Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial was written by Ntinginya, Nyanda Elias;te Brake, Lindsey;Sabi, Issa;Chamba, Nyasatu;Kilonzo, Kajiru;Laizer, Sweetness;Andia-Biraro, Irene;Kibirige, Davis;Kyazze, Andrew Peter;Ninsiima, Sandra;Critchley, Julia A.;Romeo, Renee;van de Maat, Josephine;Olomi, Willyhelmina;Mrema, Lucy;Magombola, David;Mwayula, Issakwisa Habakkuk;Sharples, Katrina;Hill, Philip C.;van Crevel, Reinout;On behalf of the PROTID Consortium. And the article was included in Trials in 2022.Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins This article mentions the following:
Diabetes mellitus (DM) increases the risk of tuberculosis (TB) and will hamper global TB control due to the dramatic rise in type 2 DM in TB-endemic settings. In this trial, we will examine the efficacy and safety of TB preventive therapy against the development of TB disease in people with DM who have latent TB infection (LTBI), with a 12-wk course of rifapentine and isoniazid (3HP). The ‘Prevention of tuberculosis in diabetes mellitus (PROTID) consortium will randomise 3000 HIV-neg. eligible adults with DM and LTBI, as evidenced by a pos. tuberculin skin test or interferon gamma release assay, to 12 wk of 3HP or placebo. Participants will be recruited through screening adult patients attending DM clinics at referral hospitals in Tanzania and Uganda. Patients with previous TB disease or treatment with a rifamycin medication or isoniazid (INH) in the previous 2 years will be excluded. The primary outcome is the occurrence of definite or probable TB disease; secondary outcome measures include adverse events, all-cause mortality and treatment completion. The primary efficacy anal. will be intention-to-treat; per-protocol analyses will also be carried out. We will estimate the ratio of TB incidence rates in intervention and control groups, adjusting for the study site using Poisson regression. Results will be reported as efficacy estimates (1-rate ratio). Cumulative incidence rates allowing for death as a competing risk will also be reported. Approx. 1000 LTBI-neg., HIV-neg. participants will be enrolled consecutively into a parallel cohort study to compare the incidence of TB in people with DM who are LTBI neg. vs pos. A number of sub-studies will be conducted among others to examine the prevalence of LTBI and active TB, estimate the population impact and cost-effectiveness of LTBI treatment in people living with DM in these African countries and address gaps in the prevention and therapeutic management of combined TB-DM. PROTID is anticipated to generate key evidence to guide decisions over the use of TB preventive treatment among people with DM as an important target group for better global TB control. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins).
8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Piperazines are very broad chemical group, covering a wide range of drugs from antidepressants to antihistamines. The connecting property of all these chemicals is the presence of a piperazine functional group.Recommanded Product: 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics